A Study of SGN-PDL1V in Advanced Solid Tumors
Latest Information Update: 21 Aug 2024
At a glance
- Drugs SGNPDL 1V (Primary)
- Indications Advanced breast cancer; Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
- Focus Adverse reactions; First in man
- Sponsors Seagen
- 19 Aug 2024 Planned number of patients changed from 332 to 438.
- 31 Jan 2024 Planned number of patients changed from 315 to 332.
- 31 Jan 2024 Patients with gastric cancer are now eligible to participate in this trial after the protocol was modified to include a treatment arm and expand the patient group.